Nucleoside Analogs
|
Pegylated interferon
with ribavirin (Al-Tawfiq et al., 2014)
|
/
|
Valeant
|
Under clinical trial for COVID-19 (ChiCTR2000029387)
|
|
Favipiravir (T-705) (De Clercq, 2019) |
A guanine analog for the
treatment of influenza virus infections |
Toyama |
Under clinical trial
for COVID-19 (ChiCTR2000029548) |
|
Remdesivir (Holshue et al., 2020) (GS-5734)
|
An adenine analog with a similar chemical structure to the approved HIV
reverse transcriptase inhibitor tenofovir alafenamide.
|
Gilead
|
Phase II clinical trial for Ebola
(NCT03719586);
Under phase III clinical trials for COVID-19 (NCT04252664)
|
Type I interferons |
IFN-β1 (Sallard et al., 2020) |
Used as a treatment
for multiple sclerosis |
Multiple companies |
Treatment of COVID-19 in
the early stage |
Protease inhibitors |
Lopinavir and ritonavir (Yamamoto et al., 2004) |
Protease inhibitors approved as anti-HIV drugs |
Abbott |
Under clinical
trials for SARS; Under clinical trial for COVID-19
(ChiCTR2000029539) |
Chloroquine |
Chloroquine and hydroxychloroquine (CDC, 2020) |
Oral
prescription drugs for treatment of malaria and certain inflammatory
conditions |
Multiple companies |
Under investigation in clinical trials
for pre-exposure or post-exposure prophylaxis of SARS-CoV-2
infection |
Antibodies |
CR3022 (Tian et al., 2020) |
A SARS Cov-specific human
monoclonal antibody |
Multiple companies |
Experimental
phase |